Search Results

Advancing Therapeutic Options Around the World Hispanic Heritage Month Happy Hispanic Heritage Month from FibroGen! During Hispanic Heritage Month, from September 15 – October 15, we celebrate the many contributions of Hispanic members of our community. In honor of this year’s Hispanic Heritage Month, we spoke with Juan Graham , Chief Financial Officer, (pictured with wife Jes and daughter Journee), about what his Hispanic heritage means to him. Where were you born? I was born in Cuernavaca - a town south of Mexico City. However, I grew up in Monterrey, Mexico, as my parents relocated there to be closer to family when I was four. When did you come to the United States? I was born in Cuernavaca - a town south of Mexico City. However, I grew up in Monterrey, Mexico, as my parents relocated there to be closer to family when I was four. How does your heritage influence your work? I believe everyone’s heritage and background allows them to view the world from different perspectives. In my case, I was fortunate enough to have a father who was a physician. My father contracted polio as a child, and he lived a life that required him to work differently. At times this disadvantage provided him with daily challenges in which he needed to be creative in solving problems. I saw my father apply this same perspective professionally and personally raising a family of three with my mother. It is this perspective that influences my work the most. Things are not always what they appear. This perspective reminds me to stay curious, and that enables me to look at challenges (and solutions) in a variety of ways—that is not always easy in the finance function. How are you raising your daughter in ways that celebrate her heritage? My daughter was born in Tokyo, Japan to a Mexican father and Nuyorican (Puerto Rican from New York) mother. There is no shortage of celebrating cultures in our household. From celebrating holidays (not just Mexican, but others), eating traditional Mexican foods, and speaking English and Spanish, my hope is that she celebrates all cultures. We hope she honors her culture as she gets older and further identifies in different ways. For now, let’s just say (and I hate to sound cliche) but there is a lot of salsa dancing, Marc Anthony and mariachi music playing at different times throughout her day. Do you feel that people of Hispanic heritage have equal opportunities in the workplace, or do we still have a way to go? I believe this question is best answered by looking at data. Minorities are underrepresented in a variety of ways from access to healthcare, under representation in clinical trials, and generally in business. This holds true for other groups too (disabled populations, economic disparities, educational disadvantages). I believe we are making progress in ways beyond representation that are starting to impact our society, and if we continue to progress, we can affect and change the trajectory of these communities. That makes me excited. What is your advice to young people of Hispanic heritage looking to get their start in biotech or finance? Learn as much as possible from the people that are willing to support and help. Find these people. Find your people - they may be in your immediate community, but they may not. The good news is there are more and more increased networks that are available. Also, have an open mind towards your career and take as many opportunities as possible and challenges that will allow you to accelerate your learning. I love Formula 1 racing and follow the only Mexican driver in the circuit – Sergio (Checo) Perez. Despite ups and downs on race weekends, he shows resilience, a steady temperament and a mindset to never give up. I am inspired by this attitude, and we have our share of ups and downs in biotech and finance… I believe the same mindset is applicable to Hispanic and non-Hispanic minorities. Is there anything else you’d like to share? I am a proud Mexican. That allows me to celebrate all things that make life grand- family, food, music, love! BUT these are things all cultures celebrate and so in that way, my celebration of these things is a celebration of ALL cultures. At FibroGen, we also honor Hispanic Heritage Month by featuring several Hispanic-owned businesses in our weekly lunch rotation, including Cuban Kitchen , Guerrero’s Taqueria , and others. How do you celebrate your heritage? Let us know in the comments! Partnering Opportunities If you are interested in partnering with us, please use the link below. CONTACT US

Contact FibroGen Contact Us FibroGen, Inc. Headquarters 350 Bay St, Ste 100 # 6009 San Francisco, CA 94133 USA Main Phone:+1 415.978.1200 Medical Information: +1 87 7 .934.34 36 (FGEN) Fax: +1 415.978.1902 Medial Information

2023 Society for Immunotherapy of Cancer (SITC) FG-3165 is a Novel Galectin-9 Neutralizing Antibody that Inhibits Galectin-9-Mediated Dimerization of TIM-3 and Galectin-9-Induced Apoptosis of CD4+ and CD8+ T Cells Prachi Bagadia, Selene Li, Mitch Brenner, Veronica Rodriguez, Mark Sternlicht, Todd Seeley, John Hunter, Dave Olsen, Gail Walkinshaw FibroGen, Inc., San Francisco, CA DOWNLOAD

Search Results 79 items found for "" Anemia | FibroGen Anemia Understanding Anemia of Chronic Kidney Disease (CKD) and Chemotherapy Induced Anemia (CIA) Anemia is a medical condition characterized by the reduced capacity of the blood to carry oxygen. Patients suffering from anemia may have insufficient levels of or impaired red blood cells and low levels of hemoglobin (Hb), an essential protein in red blood cells responsible for transporting oxygen to cells throughout the body. Anemia is associated with increased risks of hospitalization, cardiovascular complications, the need for blood transfusion, exacerbation of other serious medical conditions, and death. Even in milder forms, anemia can lead to significant fatigue, cognitive dysfunction, and decreased quality of life. The more severe the anemia, the greater the health impact on patients. ​ Severe anemia is common in patients with chronic kidney disease (CKD), cancer, inflammation, and other chronic illnesses and conditions. Despite its prevalence, when anemia develops in association with a disease for which a patient receives separate treatment, the associated anemia is often left untreated. ​ Anemia is particularly prevalent in patients with CKD, a critical healthcare problem most commonly caused by diabetes and hypertension. CKD affects more than 200 million people worldwide (KDIGO Kidney Int Suppl. 2013:S1–150), and anemia significantly increases medical care costs for those patients. CKD is generally a progressive disease characterized by the gradual loss of kidney function that may eventually lead to kidney failure, also known as end-stage renal disease (ESRD). Patients with ESRD require renal replacement therapy: either dialysis treatment or kidney transplantation. CKD accompanied by anemia is associated with worse health outcomes than CKD alone, including more rapid progression of CKD and increased death rate. ​ Although chemotherapy-induced anemia (CIA) is one of the most common side effects of chemotherapy, it is often not recognized and is frequently undertreated. CIA can adversely affect long-term patient outcomes, as the anemic environment may limit the effectiveness of some chemotherapy agents. The incidence and severity of CIA depends on a variety of factors, including the type, schedule, and intensity of therapy administered, or whether the patient has received prior myelosuppressive chemotherapy, radiation therapy, or both. An estimated 30% to 90% of cancer patients receiving chemotherapy develop anemia. Approximately 650,000 cancer patients undergo chemotherapy every year in the United States. ​ Explore Our Pipeline We are developing products with the potential to change lives. LEARN MORE ESG | FibroGen ESG ESG ESG Policy Links Environment, Health and Safety ​ At FibroGen, we have embraced a corporate vision statement across our enterprise: Our mission is to improve the lives of people globally by developing innovative therapies anchored in high-quality science and our passion for patients. ​ Further, to enable our vision of excellence, we established a set of company-wide core values: empowerment, integrity and respect. ​ Empowerment – We lead, inspire, trust and encourage each other to share ideas and assume new challenges to excel. We are accountable to each other and our commitment to our patients. ​ ​ Environment, Health and Safety For pharmaceutical companies, the product life cycle and supply chain require the use of valuable resources. FibroGen is committed to continuously reducing its environmental footprint. We adhere to California environmental, health and safety standards and city ordinances. Reports from city inspections are shared with the management and appropriate corrective actions are executed across the Company. We have i mplemented programs to recycle or donate electronic equipment when possible, provide organic compost services in the workplace, use environmentally preferred office and janitorial supplies, reduced paper waste, and have worked with our collaboration partners to reduce the amount of our product packaging and to implement good shipping practices to consolidate waste. In addition to adhering to environmental regulations, we offer a subsidized public transit commuter program, onsite electric vehicle charging stations, a flexible work from home policy, global access to video conferencing and meetings, and online medical monitoring to reduce travel. Ensuring that we have numerous programs in place to increase safety is critical to our success and fosters an experience of excellence at FibroGen. We continue to invest in lab and employee safety as well as employee health. We are also making investments in product safety and quality, and patient safety through our support of patient advocacy groups, patient support groups, expanded drug access programs, and clinical trial extensions. See our Enterprise-Level Environmental Policy ​ Social, Diversity, Equity, and Inclusion Our state-of-the-art human capital management system has significantly expanded our capabilities to develop and assess our employees. The biotechnology industry is an extremely competitive labor market and recruiting and retaining employees is critical to the continued success of our business. We are highly committed to building a diverse, dedicated, and impassioned team to deliver innovative therapies to patients facing serious unmet medical needs. Our core values of empowerment, integrity and respect for people are fundamental to how we attract, grow, engage, and retain our people. We focus on recruiting, retaining, and developing employees from a diverse range of backgrounds to conduct our research, development, commercialization, and administrative activities. ​ We consistently review and evaluate our people practices to ensure that we develop and retain a diverse, engaged and talented workforce. Our offerings include competitive, innovative and equitable pay practices, comprehensive health and wellness benefits, retirement and life insurance offerings, learning and giving programs, and flexible work arrangements. In addition to our employee and manager fundamentals learning programs, we offer wellness workouts, personal coaching and resiliency sessions, as well as access to LinkedIn Learning - an on-demand global learning management system. Our employees are offered up to 20 hours of internal career development programs each year in addition to tuition reimbursement eligibility. We build comprehensive development and succession plans at all levels in the organization to ensure that we have a strong pipeline of ready talent to meet our business outcomes. We also foster cross-functional growth opportunities and sponsor an annual promotions nomination and approval process. ​ The Company implemented pay transparency practices for all U.S. employees in December 2022. This initiative is part of our commitment to reduce gender and racial pay gaps by ensuring our pay practices are transparent for candidates and employees. Additionally, every two years, we hire outside counsel to complete a pay parity study, which includes differences in pay by gender, ethnicity, tenure and other demographic factors. We review the results of the study with the Compensation Committee of the Board and use such results to inform whether we have any gaps that need to be addressed. In our most recent pay parity study, there were no significant findings. Minor differences in pay did not trend to one gender or the other; differences were not substantial and easily attributed to variables such as years of experience, education or certifications. We have increased our human capital and diversity efforts, and we expanded our diversity dashboards for statistical reporting to ensure visibility of our recruitment candidates as well as employee demographics. ​ In 2022, FibroGen launched Women’s Network Group, which is devoted to supporting and encouraging women to develop and advance their skills and leadership potential by providing opportunities for connection, collaboration, mentorship, and support. The Group is open to all employees regardless of gender. Engagement includes such opportunities as special guest speakers, panel discussions with senior leaders, learning workshops “I am Remarkable” and book club discussions for example. In 2022, we conducted a company-wide employee engagement survey. We had an overall participation rate of 92% with over 90% of respondents reporting that they felt highly engaged. Further, for the first time an independent firm established a diversity, equity and inclusion index based upon 10 employee questions within the survey to measure the effectiveness of, and employee sentiment about, our progress in nurturing a culture of diversity, equity, belonging and inclusion; our diversity index score was 88%. These scores significantly exceed normative industry participation and engagement benchmarks. Additionally, we have facilitated training in unconscious bias, increased transparency and communications with employees through increased “Ask Me Anything” all-employee sessions and town halls, and our employee assistance programs have been expanded to include tele-health options and digital applications for expanded access. Meanwhile, we launched a collaboration, connection, communication, and recognition platform, called FibroGen Unite, Support, Engage (“F.U.S.E”). We encourage employees to use this platform to recognize each other for living our vision and values and for the everyday things we do. FibroGen believes that we have a responsibility to give back to our community by supporting career opportunities for those who would not otherwise have had access to learning, developing, and mentoring in our industry. During the summer of 2022, we partnered with NextGene Girls and Young Community Developers and re-launched our high school and college internship program by providing meaningful opportunities in science for young women and men of color and those in underserved areas. We believe that by growing a pipeline of talent today, we will benefit the biotech industry and the community at large tomorrow. In addition, we partnered again with our local community Family House and donated toys to children that are either hospitalized at or receiving treatment from UCSF’s Benioff Children’s Hospital. We also participated in and donated to the PanCAN Purple Strides Walk in Oakland, California to promote clinical trials and important research to improve the lives of patients with pancreatic cancer. See our Human Rights Policy ​ Governance and Risk Management To enhance our corporate governance efforts, we maintain an internal audit function, made substantial improvements to our Sarbanes-Oxley compliance program and strengthened our internal controls over financial reporting. Throughout the year, the Board and its Committees engage with management to discuss a wide range of enterprise risks, such as risks related to FibroGen’s businesses, cybersecurity, enterprise risk management, and they confirm the alignment of risk assessment and mitigation with business strategy. ​ In 2022, we began implementation of enterprise risk management (“ERM”) and performed an enterprise risk assessment to help us manage the risks and seize opportunities that may arise as we seek to accomplish our corporate goals. ERM has implications for all areas of our business, including how we approach new challenges and opportunities and allocate resources. One of the organic benefits of a formal ERM process is that it builds and strengthens the habit of thinking about enterprise-level, functional, and project-level risks with a patient-first mindset. Our employees, officers and directors were asked to attend meetings and workshops, and provide input via surveys to help the Company identify potential risks and ways to mitigate them. As we pursue our mission of delivering therapies in areas of significant unmet need, ERM will facilitate and support the delivery of our corporate objectives. This will be achieved through understanding and identifying risks and opportunities while putting the appropriate plans in place to capitalize on the ERM approach. ​ To better support our preparation for commercialization and scale our Company to continue meeting the needs of our patients globally, we streamlined multiple existing systems in 2022 and launched the enterprise resource planning system, System Analysis Program (“SAP”), at the beginning of 2023, covering areas such as Finance, Procurement, Supply Chain, and Manufacturing. With the implementation of this advanced technology platform, we aim to create a better, more stable user experience for employees and reduce our Company’s overall risk profile through greater reliance on automated controls. ​ With respect to cybersecurity risks, the company continually invests in new information and cybersecurity services and technologies and provides employee awareness training and information around phishing and other cybersecurity risks, with the intention to protect the company against cybersecurity risks and security breaches. ​ Our compliance program is an essential application of our core value of integrity. In November 2022, we observed Corporate Compliance & Ethics Week, with the core principles of awareness, recognition, and reinforcement of the compliance and ethics at work. Employees are enrolled in the annual compliance program, which emphasizes the shared responsibility for all colleagues to be good stewards of our organization through our commitment to maintaining the highest standards of business conduct and ethics. The annual compliance program includes certifications to confirm that employees understand and agree to abide by FibroGen’s corporate policies and guidelines, including our Anti-Bribery Policy, Code of Business Conduct and Ethics, Insider Trading and Trading Window Policy, Whistleblower Policy, and Related Persons Transactions & SEC Compliance Policy, as well as engaging video program and presentations to enhance the understanding of the Foreign Corrupt Practices Act in general and to clarify our anti-bribery and data privacy guidelines. In addition, the Company operates a telephone hotline and whistleblower website available 24 hours a day, 7 days a week, that allow employees to report unethical practices anonymously. See our Code of Vendor and Partner Conduct See our Global Code of Ethics for Clinical Trials ​ Social, Diversity, Equity, and Inclusion Governance and Risk Management Integrity – We intend to hold ourselves to the highest ethical standards in all we do: our work to bring therapies to market, the science we perform and our commitment to each other. ​ Respect for People – We strive to foster individual growth and promote an environment that supports continued learning. We stand together as a community to build and sustain a culture of diversity, equity & inclusion; and value each other’s opinion and work collaboratively to achieve optimal outcomes while treating each other with high regard and dignity. We also believe it is critical to conserve our world’s resources and strive to create a safe and healthy environment for our employees and patients. These values are an integral part of our culture, our rewards, and recognition and performance management systems. We plan to continue our efforts in 2023 in critical environmental, social, and governance (“ESG”) areas. ​ Human Rights Policy Code of Vendor and Partner Conduct Enterprise Level Environmental Policy FibroGen Global Code of Ethics for Clinical Trials Corporate Governance conference-poster-SITC2023 | FibroGen 2023 Society for Immunotherapy of Cancer (SITC) FG-3165 is a Novel Galectin-9 Neutralizing Antibody that Inhibits Galectin-9-Mediated Dimerization of TIM-3 and Galectin-9-Induced Apoptosis of CD4+ and CD8+ T Cells Prachi Bagadia, Selene Li, Mitch Brenner, Veronica Rodriguez, Mark Sternlicht, Todd Seeley, John Hunter, Dave Olsen, Gail Walkinshaw FibroGen, Inc., San Francisco, CA DOWNLOAD FibroGen Global Code of Ethics for Clini | FibroGen FibroGen Global Code of Ethics for Clinical Trials Global Code of Ethics for Clinical Trials Return to ESG Page FibroGen Global Code of Ethics for Clinic al Trials FibroGen’s mission is to improve the lives of people globally by developing innovative therapies anchored in high-quality science and our passion for patients. We treat patient safety as a top priority and hold ourselves accountable to maintain high ethical principles and standards in our clinical trials wherever they are conducted, whether by ourselves or collaboratively with our partners, contract research organizations or other third parties. All FibroGen-sponsored clinical trials are conducted in accordance with the applicable regulations, Health Authority standards, and Good Clinical Practice (GCP) guidelines. FibroGen maintains internal procedures to ensure compliance with the applicable clinical trial standards as it pertains to: ​ Appropriateness: All research should be designed to address a legitimate scientific question or need. ​ Selection of Investigators: FibroGen selects clinical investigators who have the required qualifications, training, research, clinical expertise, and the potential to recruit research participants. The independence of clinical investigators and others involved in clinical research is critical to protect the best interest of research participants. FibroGen does not engage any clinical investigators who have been debarred, disqualified, or restricted from participating in clinical research. ​ Ethical Review: FibroGen sponsored trials undergo an ethical review by a qualified independent committee (Institutional Review Board/Independent Ethics Committee) prior to study initiation. ​ Privacy: FibroGen is committed to protecting patients’ privacy, collecting minimal subject identifiers, and complying with all applicable privacy laws and regulations. ​ Integrity of Clinical Data: FibroGen ensures data are reliable and have been processed and reported correctly by using established data integrity standards. ​ Informed Consent: FibroGen requires voluntary informed consent from research participants, outlining known benefits and risks of the trial, and taking additional steps to ensure the protection of minors. ​ Safety Monitoring: FibroGen monitors patient safety throughout trials, including long-term follow-up as needed. FibroGen ensures that adverse event information regarding its products is appropriately collected, processed, reported, analyzed and communicated. FibroGen ensures clinical investigators appropriately report adverse event information and appropriately update research participants and others, as appropriate. ​ Compensation: We ensure that any payments, injury compensation, and other benefits provided to research participants are appropriate and do not unduly influence their decision to participate in a clinical research study. FibroGen payments to investigators will be within Fair Market Value (FMV) and shall be based upon the services rendered. Investigator’s Meetings: FibroGen ensures that investigator’s meetings are modest in location and cost for the purpose of training study staff on participating in a FibroGen clinical trial. FibroGen does not pay the investigators for their time but pays for modest accommodations in compliance with FibroGen’s HCP/FMV policy and local country requirements. Transparency: FibroGen makes information about its clinical trials publicly available in compliance with the applicable regulations, Health Authority standards, and GCP guidelines. We are also committed to publishing clinical trial results regardless of clinical trial outcome or regulatory approval. Diversity: FibroGen strives to conduct clinical trials without bias. We are committed to identifying and reducing the potential barriers to clinical trial access and participation, and continue to improve our subject recruitment, enrollment, and retention process to ensure disease-appropriate subject representation and greater inclusion of patients across racial, ethnic, gender, age and socioeconomic groups in our clinical trials. Pamrevlumab Trials | FibroGen Pamrevlumab Trials Pamrevlumab Trials Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), a common factor in proliferative disorders as well as certain cancer cell types. Pamrevlumab is in Phase 3 clinical studies for the treatment of metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). Pancreatic Cancer Precision PromiseSM Platform Study, Phase 2/3, Randomized, Open-label, A Multi-Center Trial Evaluating Multiple Regimens in Patients with Stage IV Metastatic Pancreatic Cancer > Active, not recruiting For more information on this study, please visit www.pancan.org LAPIS Study – FG-3019-087, Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination with Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer > Active, not recruiting For more information on the study, please contact [email protected] Privacy Notice OLD | FibroGen Privacy Notice FibroGen Privacy Notice Scope FibroGen, Inc and its subsidiaries (“FibroGen”) recognize the importance of and are committed to respecting and protecting your privacy. This Privacy Notice applies to our collection and use of “Personal Information” (which means any information from which an individual can be directly or indirectly identified) through our website and through our offline business-related interactions with you not including data from clinical trial data subjects (except where noted below). ​ Please read this Privacy Notice carefully to understand how we process Personal Information. If you do not agree with our use of your Personal Information as described in this Privacy notice, please do not use the Site, or otherwise provide Personal Information to us. ​ Privacy Notice Updates FibroGen may need to update this Privacy Notice from time to time. If so, FibroGen will post its updated Privacy Notice on our website located at www.fibrogen.com so users are always aware of what personally identifiable information we may collect and how we may use this information. FibroGen encourages you to review this Privacy Notice regularly for any changes. Your continued use of this website will be subject to the then-current Privacy Notice. ​ Information Collection and Use You can generally visit our website without revealing any personally identifiable information about yourself. However, to access certain options we may ask you to provide certain personally identifiable information such as, your name, email address, telephone number, professional credentials. Without providing such personally identifiable information, you may be unable to access certain options and services. We (and our third party partners) generally collect personally identifiable information about you only if you voluntarily provide it to us. You have the option not to provide any personally identifiable information, but we may not be able to provide you with the requested services. ​ Note that this Privacy Notice does not apply to information that we may collect through our clinical trials, which are governed by separate terms and agreements. ​ In addition, we automatically collect basic technical information from all visitors to the Site. We collect technical information during your visit to the Site through our automatic data collection tools, which may include cookies and other commonly used technologies. These tools collect certain standard information that your browser sends to the Site such as your browser type and language, access times, and the address of the Site from which you came to the Site. They may also collect information about your Internet Protocol (IP) address, or click stream data within the Site (i.e. the actions taken in connection with the Site). Please see “Cookies and other similar technologies” below for additional detail about the information we collect through cookies and other commonly used technologies. How we use your Personal Information Subject to applicable data protection laws, we may use your Personal Information for the following purposes: (i) to provide you with the services and information offered through the Site; (ii) to contact you and respond to your requests and inquiries; (iii) for business administration, including answering questions or inquiries, job submissions, and statistical analysis; (iv) to personalize your visit to the Site and to assist you while you use the Site; (v) to improve the Site by helping us understand who uses the Site; (vi) for fraud prevention and detection and to comply with applicable laws, regulations or codes of practice. ​ Sharing of your Personal Information We may provide your personally identifiable information that we collect, and the data generated by cookies to a parent, subsidiary or affiliate entity related to FibroGen, partner entities, and the vendors and service agencies that we may engage to assist us. Any organization to which we provide such personally identifiable information is required to respect the security of your personal data and keep your personally identifiable information confidential in accordance with this Privacy Notice. We do not allow our third-party service providers to use your personal data for their own purposes and only permit them to process your personal data for specified purposes and in accordance with our instructions ​ Similarly, we may share your Personal Information as required or permitted by law to comply with a subpoena or similar legal process or government request, or when we believe in good faith that disclosure is legally required or otherwise necessary to protect our rights and property, or the rights, property or safety of others, including to advisers, law enforcement, judicial and regulatory authorities. We may also transfer your Personal Information to a third party in the event of any reorganization, merger, sale, joint venture, assignment, transfer or other disposition of all or any portion of our business, assets, or shares (including in connection with any bankruptcy or similar proceedings.) ​ The servers used in the operation of the Site automatically identify a computer by its IP address. If we, in good faith, determine that you have or are attempting to misuse or harm the Site, we may investigate and cooperate with appropriate law enforcement to protect our rights or property. ​ International data transfers By using the Site or otherwise providing Personal Information to us, you hereby expressly consent to the transfer of your Personal Information outside your country or region. ​ FibroGen complies with applicable privacy laws to ensure an adequate level of data protection. You can request more information about these measures by contacting us at the phone number or email address below. EU-U.S. Privacy Shield [and Swiss-U.S. Privacy Shield] ​ FibroGen and its affiliates have self-certified to the EU-U.S. Privacy Shield Framework and the Swiss-U.S. Privacy Shield Framework (together the “Privacy Shield”) as set forth by the U.S. Department of Commerce, and they adhere to the Privacy Shield Principles (the “Principles”) regarding the processing of Personal Information transferred from organizations in the EU and Switzerland to FibroGen in the U.S. To learn more about the Privacy Shield program, and to view FibroGen’s certification, please visit http://www.privacyshield.gov . ​ FibroGen shall remain liable under the principles if a third party agent uses or discloses Personal Information received from FibroGen in a manner inconsistent with the Principles, unless FibroGen proves that it is not responsible for the event giving rise to the damage. ​ Your rights Access Upon request, FibroGen will provide individuals with reasonable access to Personal Information about them. FibroGen will also take reasonable steps to allow individuals to review Personal Information for the purposes of correcting, amending, or deleting such information in instances where Personal Information is demonstrated to be incomplete or inaccurate. California Residents have rights under the California Consumer Privacy Act (CCPA) as follows: The right to know about the Personal Information a business collects about and how it is used and shared. The right to delete Personal Information collected from (with some exceptions); The right to opt-out of the sale of their Personal Information; and The right to non-discrimination for exercising their CCPA rights. California’s “Shine The Light” law permits California residents to annually request and obtain information free of charge about what Personal Information is disclosed to third parties for third-party direct marketing purposes in the preceding calendar year. FibroGen does not distribute your Personal Information to third parties for third-party direct marketing purposes, except as provided for in this Privacy Notice. ​ FibroGen does not sell personal Information. Per the CCPA, Individuals can contact FibroGen at [email protected] or at 1 (888) 810-0874 to request access or to make inquiries regarding limiting the use and disclosure of Personal Information about them. ​ Individuals in certain jurisdictions have data subject rights which may be subject to limitations and/or restrictions. These rights may include the right to: (i) request access to and correction or erasure of their Personal Information; (ii) obtain restriction of processing or to object to processing of their Personal Information; and (iii) require data portability. ​ If you wish to exercise one of the above-mentioned rights, please send us your request via email to: [email protected] . Individuals from the European Union, Switzerland, and UK also have the right to lodge a complaint about the processing of their Personal Information with their local data protection supervisory authority. ​ No fee usually required You will not have to pay a fee to access your personal data (or to exercise any of the other rights). However, we may charge a reasonable fee if your request is clearly unfounded, repetitive or excessive. Alternatively, we may refuse to comply with your request in these circumstances. ​ What we may need from you We may need to request specific information from you to help us confirm your identity and ensure your right to access your personal data (or to exercise any of your other rights). This is a security measure to ensure that personal data is not disclosed to any person who has no right to receive it. We may also contact you to ask you for further information in relation to your request. ​ Security and retention of your Personal Information The security of your Personal Information is important to us. We take reasonable steps, including technical, administrative, and physical safeguards, designed to protect the Personal Information submitted to us from loss, misuse and unauthorized access, disclosure, alteration, and destruction. However, no method of security or method of transmission over the Internet is entirely secure. You should always use caution when transmitting Personal Information over the Internet. ​ We may retain your Personal Information for as long as your account is active or as needed for the specific business purpose for which it was collected. In some cases, we may be required to retain information to comply with laws or regulations or other legal obligations, resolve disputes and enforce our agreements. ​ Cookies and Other Similar Technologies Cookies are small text files that are stored on computer hard drives by websites that you visit. There are two general types of cookies, session cookies and persistent cookies. Session cookies are only used during a session online and will be deleted once you leave a website. Persistent cookies have a longer life and will be retained by the website and used each time you visit a website. Both session and persistent cookies can be deleted by you at anytime through your browser settings. ​ We use the following session and persistent cookies on the Site: Strictly necessary cookies: these session cookies are essential for visitors to move around the Site and use its features. Analytical / performance cookies: these session cookies allow us to recognize and count the number of visitors and to see how visitors move around our Site when they are using it. This helps us to improve the way our Site works, for example, by ensuring that users are finding what they are looking for easily. Functionality cookies: these persistent cookies are used to recognize you when you return to our Site. This enables us to personalize our content for you and remember your preferences. ​ ​ We may track the total number of visitors to our website or use such information, individually or in the aggregate, to analyze trends, administer the website, track user’s movement, and gather broad demographic information for use. We may share this information with our corporate partners and contracted vendors to assist us in operating the website and to enable them to better understand FibroGen’s business. ​ Web browsers often allow you to erase existing cookies from your hard drive, block the use of cookies and/or be notified when cookies are encountered. If you elect to block cookies, please note that you may not be able to take full advantage of the features and functions of the Site. To find out more about cookies, including how to see what cookies have been set and how to manage and delete them, please visit www.allaboutcookies.org . ​ Please note that third parties (including, for example, advertising networks and providers of external services like web traffic analysis services) may also use cookies on our website, over which we have no control. ​ External links The Site contains links to external Sites operated by third parties. We are not responsible for these third party Sites or the content of such third party sites. Once you have left the Site, we cannot be responsible for the protection and privacy of any information, which you provide. You should exercise caution and look at the privacy notice for the website you visit. ​ Children This Site is not directed towards children under 18 years of age, nor do we knowingly collect information from children under 18. If you are under 18, please do not use the Site or submit any Personal Information to us. If you believe that we have unintentionally collected Personal Information about your child, you can contact us as described below. ​ Dispute Resolution With respect to Personal Information transferred or received pursuant to the Privacy Shield, FibroGen is subject to the investigatory and enforcement powers of the U.S. Federal Trade Commission. In certain instances, FibroGen may be required to disclose Personal Information in response to lawful requests by public authorities, including to meet national security or law enforcement requirements. FibroGen commits to resolve complaints about our collection or use of your personal information. Individuals from European Union, UK, and Switzerland with inquiries or complaints regarding our Privacy Shield notice should first contact FibroGen at: Address: 409 Illinois Street, San Francisco, CA 94158, USA Tel.: 1 (888) 810-0874 Email: [email protected] ​ FibroGen has further committed to refer unresolved complaints to JAMS Privacy Shield program, an alternative dispute resolution provider located in the United States. If you do not receive timely acknowledgment of your complaint from us, or if we have not addressed your complaint to your satisfaction, please visit www.jamsadr.com/eu-us-privacy-shield for more information or to file a complaint. Contacting JAMS is at no cost to you. Under certain circumstances, an individual may choose to invoke binding arbitration to resolve any Privacy Shield disputes that have not been resolved by other means. Copy of old R&D Pipeline | FibroGen R&D Pipeline FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD) and chemotherapy induced anemia (CIA), Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer. The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases. ​ HIF Platform Preclinical Phase 1 Phase 2 Phase 3 Approved United States ROXADUSTAT (HIF-PHI) ANEMIA OF CKD CRL Received China Approved Europe Approved Japan Approved 1 FDA issued a complete response letter on 8/10/21 1 Phase 3 China ROXADUSTAT (HIF-PHI) ANEMIA IN CIA Fibrotic Disease Platform Preclinical Phase 1 Phase 2 Approved Phase 3 Locally Advanced Pancreatic Cancer Duchenne Muscular Dystrophy PAMREVLUMAB (ANTI-CTGF ANTIBODY) Phase 3 Phase 3 PARTNERED WHOLLY-OWNED Roxadustat Pamrevlumab Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. LEARN MORE Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin. LEARN MORE Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. Code of Vedor and Partner Conduct Policy | FibroGen Code of Vendor and Partner Conduct Policy Return to ESG Page Code of Vendor and Partner Conduct Policy Code of Vendor and Partner Conduct ​ To fulfill our vision in improving the lives of people globally, FibroGen partners with third-party individuals and organizations who share FibroGen’s values and commitments to act in an ethical, compliant and socially responsible manner throughout the business engagement and continue to improve their efforts on advancing performance over time. These vendors and other third-parties are expected to operate in full compliance with all applicable laws, rules and regulations, at a minimum, as well as adopt and comply with their own code of business ethics and conduct, which should include ethical principles and standards regarding labor and human rights, equal opportunity and non-discrimination, diverse workforce and pay equity, health and safety, environmental sustainability, anti-bribery, data privacy and information protection, trade sanctions and exports control, quality, and management systems. ​ Publications | FibroGen Publications Publications Featuring Roxadustat Roxadustat for Chemotherapy-Induced Anemia in Patients with Non-Myeloid Malignancies: A Randomized, Open-Label, Active-Controlled, Phase III Study Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study Roxadustat for the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ALPS) Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD Roxadustat for anemia in patients with end-stage renal disease incident to dialysis Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES) A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis Publications Featuring Pamrevlumab Pamrevlumab, An Anti-Connective Tissue Growth Factor Therapy, For Idiopathic Pulmonary Fibrosis (PRAISE): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial Pamrevlumab In Idiopathic Pulmonary Fibrosis Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis FG-3019, a Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Journal of Cancer Clinical Trials FG-3019, A Human Monoclonal Antibody Targeting connective tissue Growth Factor, is Subject to Target-Mediated Drug Disposition FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy Publications Featuring FG-3165 FG-3165 is a Novel Galectin-9 Neutralizing Antibody that Inhibits Galectin-9-Mediated Dimerization of TIM-3 and Galectin-9-Induced Apoptosis of CD4+ and CD8+ T Cells Explore Our Pipeline We are developing products with the potential to change lives. LEARN MORE Copy of Anemia | FibroGen Anemia Understanding Anemia of Chronic Kidney Disease (CKD), Chemotherapy Induced Anemia (CIA) and Myelodysplastic Syndromes (MDS) Anemia is a medical condition characterized by the reduced capacity of the blood to carry oxygen. Patients suffering from anemia may have insufficient levels of or impaired red blood cells and low levels of hemoglobin (Hb), an essential protein in red blood cells responsible for transporting oxygen to cells throughout the body. Anemia is associated with increased risks of hospitalization, cardiovascular complications, the need for blood transfusion, exacerbation of other serious medical conditions, and death. Even in milder forms, anemia can lead to significant fatigue, cognitive dysfunction, and decreased quality of life. The more severe the anemia, the greater the health impact on patients. ​ Severe anemia is common in patients with chronic kidney disease (CKD), cancer, myelodysplastic syndromes (MDS), inflammation, and other chronic illnesses and conditions. Despite its prevalence, when anemia develops in association with a disease for which a patient receives separate treatment, the associated anemia is often left untreated. ​ Anemia is particularly prevalent in patients with CKD, a critical healthcare problem most commonly caused by diabetes and hypertension. CKD affects more than 200 million people worldwide (KDIGO Kidney Int Suppl. 2013:S1–150), and anemia significantly increases medical care costs for those patients. CKD is generally a progressive disease characterized by the gradual loss of kidney function that may eventually lead to kidney failure, also known as end-stage renal disease (ESRD). Patients with ESRD require renal replacement therapy: either dialysis treatment or kidney transplantation. CKD accompanied by anemia is associated with worse health outcomes than CKD alone, including more rapid progression of CKD and increased death rate. ​ Although chemotherapy-induced anemia (CIA) is one of the most common side effects of chemotherapy, it is often not recognized and is frequently undertreated. CIA can adversely affect long-term patient outcomes, as the anemic environment may limit the effectiveness of some chemotherapy agents. The incidence and severity of CIA depends on a variety of factors, including the type, schedule, and intensity of therapy administered, or whether the patient has received prior myelosuppressive chemotherapy, radiation therapy, or both. An estimated 30% to 90% of cancer patients receiving chemotherapy develop anemia. Approximately 650,000 cancer patients undergo chemotherapy every year in the United States. ​ Myelodysplastic syndromes (MDS) are a group of disorders characterized by poorly formed or dysfunctional blood cells, resulting in chronic anemia in most patients. Anemia in MDS patients is associated with increased risk of hospitalization, cardiovascular complication, need for blood transfusion, exacerbation of other serious medical conditions, and death. In addition, anemia frequently leads to significant fatigue, cognitive dysfunction, and decreased quality of life. Currently, there are few options available for treating anemia in MDS. Patients with MDS typically rely on repeated blood transfusions. Further, in most MDS patients in China, anemia is under-treated due to limited blood supply and challenges in accessing transfusions. Explore Our Pipeline We are developing products with the potential to change lives. LEARN MORE Pamrevlumab | FibroGen Pamrevlumab Investigating the Groundbreaking Potential of Anti-CTGF Therapy Pamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in proliferative disorders as well as certain cancer cell types. Pamrevlumab is in Phase 3 clinical development for the treatment of metastatic pancreatic cancer, locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD), and Fast Track designation to pamrevlumab for the treatment of patients with LAPC, and DMD. The U.S. Food and Drug Administration has also granted Rare Pediatric Disease Designation to pamrevlumab for the treatment of patients with DMD. Pamrevlumab has demonstrated a safety and tolerability profile that has supported ongoing clinical investigation in LAPC, and DMD. Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov. Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. Pamrevlumab Trials Developing unprecedented options for patients with DMD. LEARN MORE Our Culture | FibroGen Our Culture A Commitment to Science and Medical Innovation At FibroGen, we seek to change peoples’ lives by bringing innovative therapies to life. We are motivated, curious, and passionate thinkers who believe in doing something truly important. Our Values At FibroGen, we value collaboration, extraordinary talent, and innovative thinking that brings us closer to our goals of helping patients and enriching lives. Our Values were developed by and for employees and represent our commitment to our science, our patients, and each other. Excellence The core of our values is predicated upon applying excellence in all that we do Empowerment We lead, inspire, trust and encourage each other to share ideas and assume new challenges to excel ​ ​ We are accountable to each other and our commitment to our patients Integrity We hold ourselves to the highest ethical standards in all we do; our work to bring therapies to market, the science we perform and our commitment to each other​ ​ ​ We expect honesty and fairness and transparency from each other Respect for People We foster individual growth and promote an environment that supports continued learning ​ ​ We stand together as a community to build and sustain a culture of inclusiveness and equality ​ We believe it is critical to conserve our world’s resources and strive to create a safe and healthy environment for our employees and patients. ​ ​ We commit to treating each other with high regard and dignity Benefits At FibroGen, we offer a comprehensive benefits program to help our employees thrive in all areas of life. We offer competitive, high-quality support programs that enable you to do your very best work in a positive, safe, and healthy environment. Health and Wellness Comprehensive, affordable healthcare coverage is available. Medical plan options offered to our employees include: PPO or HMO Prescription drug, vision, and dental coverage On-site fitness facility that is free to our employees and offers top of the line equipment, classes, and personal training on an individual basis Disability Coverage and Life Insurance FibroGen helps employees prepare for the unexpected (and expected) and protect against life’s challenges by offering: Company-paid short-term disability (STD) and long-term disability (LTD) Company-paid basic life insurance Business travel accident insurance coverage Family leave, including maternity and paternity leave Financial Benefits FibroGen’s competitive benefits program gives employees financial protection throughout their careers at FibroGen and helps them prepare for a financially secure future through: Annual bonus program 401(k) retirement and savings plan (FibroGen matches employee contributions dollar-for-dollar with immediate vesting, up to a maximum percent of salary based on years of service) Incentive stock plan Employee Stock Purchase Plan (ESPP) through which employees can buy company stock at a discount Flexible Spending Account (FSA) Dependent-Care Spending Account (DCFSA) Pre-tax commuter programs, free onsite parking, and access to Mission Bay Shuttle, BART, and Caltrain Employee referral program Credit Union Other Benefits FibroGen knows it can be challenging to balance life’s competing commitments and priorities. For this reason, we offer: Competitive annual vacation time, paid holidays (including a summer and year-end holiday shutdown), and personal wellness days Tuition reimbursement plan Employee sponsorship for professional memberships and conferences to enhance professional development Employee Assistance Program (EAP) providing consultations for a wide range of personal topics at no cost NOTICE: The foregoing is a general description of FibroGen benefits, which are subject to change or discontinuation at any time. Explore Career Opportunities View current job openings. FIND JOBS Previous 1 2 3 4 5 6 7 Next

There’s Nothing Here... We can’t find the page you’re looking for. Check the URL, or head back home. Go Home

Thane Wettig Executive Vice President, Chief Commercial Officer Mr. Wettig, Executive Vice President, Chief Commercial Officer, joined FibroGen in June of 2020 and brings more than 30 years of global biopharmaceutical leadership and experience. Mr. Wettig previously served as Chief Commercial Officer and Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining Intarcia in 2018, he served as Vice President of Global Marketing, Strategy and Alliance Management for Lilly Diabetes, leading the development and launch of multiple blockbuster diabetes medicines during a period of unprecedented growth of Lilly’s diabetes business. Mr. Wettig also played an integral role in the design and management of Lilly’s highly successful diabetes alliance between Lilly and Boehringer-Ingelheim. He is recognized throughout the industry as a seasoned executive with extensive launch experience. Mr. Wettig received his M.B.A. and B.A. in biology from Washington University in St. Louis. Close

Mark Eisner, M.D., M.P.H. Executive Vice President, Chief Medical Officer Dr. Eisner, Executive Vice President, Chief Medical Officer, joined the company in December of 2020, overseeing all global clinical development and regulatory affairs for FibroGen. Dr. Eisner brings nearly 30 years of academic, biopharmaceutical, and drug development experience, from early clinical phase through post-commercialization. Prior to joining FibroGen, Dr. Eisner was at Genentech, a member of the Roche Group, and was Senior Vice President and Global Head of Product Development Immunology, Infectious Disease, and Ophthalmology. He also served on the Board of the Genentech Foundation, a private charitable foundation that supports educational and community organizations. ​ ​Prior to Genentech, Mark was Professor of Medicine and Anesthesia at the University of California San Francisco. Dr. Eisner received an A.B. degree from Stanford University in Human Biology and then received his M.D. degree from the University of Pennsylvania School of Medicine. He completed residency training in internal medicine, served as Chief Medical Resident, and pursued advanced fellowship training in pulmonary and critical care medicine at the University of California, San Francisco. He also received a M.P.H. degree from the University of California, Berkeley School of Public Health. Close

Kalevi Kurkijärvi, Ph.D. Director Kalevi Kurkijärvi, Ph.D., has served on our board of directors since November 1996. He has also served on the board of directors of our subsidiary, FibroGen Europe Oy, since November 1997, and as Managing Director (CEO) since January 2019. Dr. Kurkijärvi has been the Chairman and Founding Partner of Innomedica Oy, a business development company specialized in licensing, distributor search, and strategic planning for companies in the pharmaceutical, diagnostics, and biotechnology industries, since March 2010, and from August 1997 to February 2010 he acted as Director, with financial matters as his main responsibility. He was also the Founding Partner and former Chairman and Chief Executive Officer of Bio Fund Management Ltd., a Finnish-Danish venture capital company, from 1997 until 2010. He has also been Chairman and Chief Executive Officer of his family’s import-export trading company, Biketex Ltd., since October 1993. Dr. Kurkijärvi has more than twenty years of experience in international life science business and over ten years in corporate finance. He currently serves on the boards of directors of Innomedica Oy (chair), Biketex Ltd. (chair), and Idea Development ID Oy (chair). He previously served on the boards of directors at other biotechnology companies such as Paratek Pharmaceuticals Inc., Ark Therapeutics Plc, BioTie Therapies Plc (chair), Hytest Oy (chair), Stick Tech Oy (chair), Hormos Medical Oy (chair), Map Medical Oy (chair), Bio Orbit Oy (chair), and Juvantia Pharma Oy, among others. Prior to founding Bio Fund, Dr. Kurkijärvi worked as Executive Director of the venture capital group at the Finnish National Fund of Research and Development (SITRA). He has also served as Executive Vice President at Wallac Oy, and as President and Chief Executive Officer of Pharmacia Diagnostics Production Oy. Dr. Kurkijärvi received a Ph.D. in Biochemistry and Molecular Biology from the University of Turku in 1992, where he also worked for several years in research and teaching. Close

Aoife Brennan, M.B., B.Ch. Director Aoife Brennan, M.B., B.Ch., was appointed to our board of directors in August 2020. Dr. Brennan is President and CEO of Synlogic, Inc. She joined Synlogic as Chief Medical Officer in September 2016 and was promoted to CEO in October 2018. Prior to joining Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX®, ELOCTATE® and SPINRAZA® as well as the advancement of several early-phase programs and external collaborations. She served as a Director of Ra Pharmaceuticals from September 2018 through their acquisition in April 2020 and has served as a Director of Cerevance since January 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. Close

Joe, M.B., B.Ch. Director Holder Close

James A. Schoeneck Chairman of the Board James A. Schoeneck was appointed Chairperson of our Board of Directors in January 2020 and has served on our board of directors since April 2010. Following the unexpected passing of Thomas B. Neff, FibroGen’s Founder and Chief Executive Officer, Mr. Schoeneck served as Interim Chief Executive Officer from August 2019 until January 2020. Mr. Schoeneck was Chief Executive Officer of Depomed, Inc., a commercial specialty pharmaceutical company, from 2011 until 2017, and joined the Board of Depomed in 2007. In addition, from 2015 to 2018, Mr. Schoeneck served on the board of directors of AnaptysBio, Inc. From 2005 until 2011, he was Chief Executive Officer of BrainCells, Inc., a privately held biopharmaceutical company. Prior to joining BrainCells, Inc., he served as Chief Executive Officer of ActivX Biosciences, Inc., a development-stage biotechnology company. Mr. Schoeneck’s pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc., a pharmaceutical and diagnostics products company. Prior to joining Prometheus, Mr. Schoeneck spent three years as Vice President and General Manager, Immunology, at Centocor, Inc. (now Janssen Biotech, Inc.), a biotechnology company, where he led the development of Centocor’s commercial capabilities. His group launched Remicade®, which became one of the world’s largest pharmaceutical brands. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi), a pharmaceutical company, serving in various sales and marketing positions of increasing responsibility. Since July 2020, Mr. Schoeneck has served on the board of Calidi Biotherapeutics, a cancer therapeutics company focused on oncolytic viruses and stem cells. Mr. Schoeneck holds a B.S. in Education from Jacksonville State University. Close

Suzanne Blaug Director Suzanne Blaug has more than 30 years of strategic and commercial experience in the biopharmaceutical industry. She has successfully brought new drugs to market at the global, regional, and local country levels in multiple therapeutic areas including oncology, cardiovascular, immunology, nephrology, infectious diseases, neurology, and psychiatry. Ms. Blaug most recently served as Senior Vice President, Global Marketing and Commercial Development at Amgen Inc. from 2012 to 2018. From 2004 until 2012, she was at Johnson & Johnson, where she held several positions including Head of Janssen Alzheimer Immunotherapy, Vice President Strategic Marketing and New Business Development at Janssen Europe, and Area Managing Director – UK, Italy, and Greece. Ms. Blaug started her career at Bristol-Myers Squibb in 1983, where she held numerous marketing, strategic, and general management positions in the U.S., Europe, Australia, and New Zealand. Ms. Blaug is currently a senior advisor at McKinsey & Company, and she serves on the Healthcare at Kellogg Advisory Council at Northwestern University, as well as the Center for the Business of Healthcare Corporate Advisory Board at the University of North Carolina. Ms. Blaug received her B.S. degree from the University of North Carolina at Chapel Hill, and her M.B.A. from the Kellogg School of Management at Northwestern University. Close